Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.50 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
| ▸ | TPH1 | P17752 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7370483 | 0.88 | F2 (0.47) | F2KAT6AF10PLGPLAT | |
| SCHEMBL7440975 | 0.86 | F2 (0.53) | F2F10PLGPLATPRSS1 | |
| SCHEMBL8743773 | 0.78 | F2 (0.52) | F2KAT6AF10PLATPOLB | |
| SCHEMBL3419341 | 0.74 | F2 (0.60) | F2KAT6AF10PLGPLAT | |
| SCHEMBL3057528 | 0.74 | F2 (0.60) | F2KAT6AF10PLGPLAT | |
| SCHEMBL5171526 | 0.71 | SLC7A5 (0.50) | F2SLC1A3SLC1A2SLC1A1TPH1 | |
| SCHEMBL5171532 | 0.71 | SLC7A5 (0.50) | F2SLC1A3SLC1A2SLC1A1TPH1 | |
| SCHEMBL6848743 | 0.71 | KAT6A (0.63) | F2KAT6AF10PRSS1PRSS2 | |
| SCHEMBL4351626 | 0.70 | SLC7A5 (0.51) | TPH1 | |
| SCHEMBL16792856 | 0.70 | TPH1 (0.60) | TPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777431-B2 | ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. | 2004-08-17 | — | — | US | disclosed |
| WO-2001079195-A9 | PYRIDINE AND PYRAZINE DERIVATIVES AS THROMBIN INHIBITORS | CORVAS INT INC (US) | 2003-10-23 | — | — | WO | disclosed |
| US-6608204-B1 | Peptide aldehyde having arginine or arginine mimics at P1 and pyridone, pyrimidone, or uracil groups; antithrombosis agents | CORVAS INTERNATIONAL, INC. | 2003-08-19 | — | — | US | disclosed |
| US-20030092679-A1 | Novel non-convalent thrombin inhibitors | DENDREON PHARMACEUTICALS LLC | 2003-05-15 | — | — | US | disclosed |
| US-6541467-B1 | And at P1 have a six-membered heterocyclic ring having two ring nitrogen ring atoms and the remainder of the ring atoms carbon atoms. | CORVAS INTERNATIONAL, INC. | 2003-04-01 | — | — | US | disclosed |
| US-6506761-B1 | Compound of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: | CORVAS INTERNATIONAL, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6506754-B1 | Compounds as anticoagulants | CORVAS INTERNATIONAL, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6506760-B1 | Compounds of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: | CORVAS INTERNATIONAL, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-0804464-B1 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INT INC (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6342504-B1 | PEPTIDES AS ANTITHROMBINS AND ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. | 2002-01-29 | — | — | US | disclosed |
| EP-0765338-B1 | ARGININE MIMIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INT INC (US) | 1999-04-21 | — | — | EP | disclosed |
| EP-0765339-B1 | 3-AMINO-2-OXO-1-PIPERIDINEACETIC DERIVATIVES CONTAINING AN ARGININE MIMIC AS ENZYME INHIBITORS | CORVAS INT INC (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997046207-A2 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0804464-A1 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0765338-A1 | ARGININE MIMIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1997-04-02 | — | — | EP | disclosed |
| EP-0765339-A1 | 3-AMINO-2-OXO-1-PIPERIDINEACETIC DERIVATIVES CONTAINING AN ARGININE MIMIC AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1997-04-02 | — | — | EP | disclosed |
| WO-1996018644-A9 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | — | 1996-08-01 | — | — | WO | disclosed |
| WO-1996018644-A1 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1996-06-20 | — | — | WO | disclosed |
| WO-1995035313-A1 | 3-AMINO-2-OXO-1-PIPERIDINEACETIC DERIVATIVES CONTAINING AN ARGININE MIMIC AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1995-12-28 | — | — | WO | disclosed |
| WO-1995035312-A1 | ARGININE MIMIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092679-A1 | Novel non-convalent thrombin inhibitors | F2, SERPINC1, F2RL3 | F2 1/4885KAT6A 4381/4885F10 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.